title: Effect of dopaminergic substances on sleep/wakefulness in saline- and MPTP-treated mice.
abstract: Sleep/wakefulness (S/W) disorders are frequent in Parkinson's disease (PD). The underlying causes have yet to be elucidated but dopaminergic neurodegenerative lesions seem to contribute to appearance of the disorders and anti-Parkinsonian medication is known to accentuate S/W problems. Hence, we reasoned that studying the acute effect of dopaminergic compounds on S/W in an animal model of PD might improve our knowledge of S/W regulation in the context of partial dopaminergic depletion. To this end, we tested the effect of levodopa (l-dopa), pergolide (a mixed D(2)/D(1) agonist) and lisuride (a D(2) agonist) on S/W recordings in MPTP-treated mice, in comparison with controls. Our results showed that dopaminergic compounds modify S/W amounts in both control and MPTP mice. Wakefulness amounts are greater in MPTP mice after l-dopa (50 mg kg(-1)) and lisuride (1 mg kg(-1)) injections compared with control mice. Moreover, the paradoxical sleep latency was significantly longer in MPTP mice after high-dose l-dopa administration. Our observations suggest that the actions of both l-dopa and lisuride on S/W differ slightly in MPTP mice relative to controls. Hence, MPTP-induced partial DA depletion may modulate the effect of dopaminergic compounds on S/W regulation.
authors.affiliation: Laboratoire de Physiologie, Institut Fédératif de Recherche, Faculté de Médecine, Pôle recherce, Lille cedex, France.
authors.forename: Charlotte
authors.initials: C
authors.lastname: Laloux
authors.forename: Philippe
authors.initials: P
authors.lastname: Derambure
authors.forename: Elise
authors.initials: E
authors.lastname: Houdayer
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Jacquesson
authors.forename: Régis
authors.initials: R
authors.lastname: Bordet
authors.forename: Alain
authors.initials: A
authors.lastname: Destée
authors.forename: Christelle
authors.initials: C
authors.lastname: Monaca
mesh_terms: D000818:Animals; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D004569:Electroencephalography; D007980:Levodopa / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D008090:Lisuride / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D020734:Parkinsonian Disorders / Q000188:drug therapy*; D010479:Pergolide / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D017286:Polysomnography; D012890:Sleep / Q000187:drug effects*; D014851:Wakefulness / Q000187:drug effects*
chemical_list: D018491:Dopamine Agonists; D010479:Pergolide; D007980:Levodopa; D008090:Lisuride